Retrospective genome analysis of a live vaccine strain of bovine viral diarrhea virus

A. Bálint, Claudia Baule, V. Pálfi, Sándor Belák

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A live bovine viral diarrhea (BVDV) vaccine, marketed as a derivate of the Oregon C24V strain, was used between the end of the 1960s and the beginning of the 1990s in Central Europe. Since laboratory investigations of mucosal disease cases in vaccinated animals suggested recombinations between the vaccine and wild type variants of BVDV, and recombinational nucleotide sequences seemed distinct from BVDV Oregon C24V, the aim of the present retrospective study was to analyze the genomes of pre-registration (termed here BVDV-Xpre) and of marketed (BVDV-X) batches of the vaccine. The results of the complete genome analysis of BVDV-Xpre confirmed that the original virus strain used at the start of the vaccine production was Oregon C24V. Surprisingly, the analysis of the complete nucleotide sequence of the BVDV-X marketed vaccine revealed that this strain belongs to the BVDV 1b subgroup, with a 93.7% nucleotide sequence homology to BVDV reference strain Osloss. The homology to BVDV Oregon C24V was significantly lower (77.4%), and a thorough sequence scanning showed that the genome of BVDV-X had not derived from Oregon C24V. These data indicate the very likely scenario that a strain different to Oregon C24V was picked up during the in vitro or in vivo passages for vaccine development. Despite of the virus-switch, the BVDV-X vaccine continuously maintained its innocuity and efficacy, as proven by the regular quality testing data, and the presence of the foreign virus remained unnoticed over many years. The results of this work emphasize that the contamination of commercially available live vaccines with exogenous BVDV strains is a real risk factor, and a unequivocal analysis, including molecular methods, is needed to verify their authenticity.

Original languageEnglish
Pages (from-to)89-99
Number of pages11
JournalVeterinary Research
Volume36
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Bovine Viral Diarrhea Viruses
Bovine viral diarrhea virus
live vaccines
Vaccines
Genome
vaccines
genome
nucleotide sequences
viruses
Viruses
bovine viral diarrhea
vaccine development
sequence homology
retrospective studies
Central European region
risk factors
Sequence Homology
Genetic Recombination
Diarrhea
Retrospective Studies

Keywords

  • Bovine viral diarrhea virus
  • Control
  • Strain switch
  • Vaccine

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Retrospective genome analysis of a live vaccine strain of bovine viral diarrhea virus. / Bálint, A.; Baule, Claudia; Pálfi, V.; Belák, Sándor.

In: Veterinary Research, Vol. 36, No. 1, 01.2005, p. 89-99.

Research output: Contribution to journalArticle

@article{fe9e0fd4f6014fb3a046489609c9c2f0,
title = "Retrospective genome analysis of a live vaccine strain of bovine viral diarrhea virus",
abstract = "A live bovine viral diarrhea (BVDV) vaccine, marketed as a derivate of the Oregon C24V strain, was used between the end of the 1960s and the beginning of the 1990s in Central Europe. Since laboratory investigations of mucosal disease cases in vaccinated animals suggested recombinations between the vaccine and wild type variants of BVDV, and recombinational nucleotide sequences seemed distinct from BVDV Oregon C24V, the aim of the present retrospective study was to analyze the genomes of pre-registration (termed here BVDV-Xpre) and of marketed (BVDV-X) batches of the vaccine. The results of the complete genome analysis of BVDV-Xpre confirmed that the original virus strain used at the start of the vaccine production was Oregon C24V. Surprisingly, the analysis of the complete nucleotide sequence of the BVDV-X marketed vaccine revealed that this strain belongs to the BVDV 1b subgroup, with a 93.7{\%} nucleotide sequence homology to BVDV reference strain Osloss. The homology to BVDV Oregon C24V was significantly lower (77.4{\%}), and a thorough sequence scanning showed that the genome of BVDV-X had not derived from Oregon C24V. These data indicate the very likely scenario that a strain different to Oregon C24V was picked up during the in vitro or in vivo passages for vaccine development. Despite of the virus-switch, the BVDV-X vaccine continuously maintained its innocuity and efficacy, as proven by the regular quality testing data, and the presence of the foreign virus remained unnoticed over many years. The results of this work emphasize that the contamination of commercially available live vaccines with exogenous BVDV strains is a real risk factor, and a unequivocal analysis, including molecular methods, is needed to verify their authenticity.",
keywords = "Bovine viral diarrhea virus, Control, Strain switch, Vaccine",
author = "A. B{\'a}lint and Claudia Baule and V. P{\'a}lfi and S{\'a}ndor Bel{\'a}k",
year = "2005",
month = "1",
doi = "10.1051/vetres:2004053",
language = "English",
volume = "36",
pages = "89--99",
journal = "Annales de Recherches Veterinaires",
issn = "0928-4249",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Retrospective genome analysis of a live vaccine strain of bovine viral diarrhea virus

AU - Bálint, A.

AU - Baule, Claudia

AU - Pálfi, V.

AU - Belák, Sándor

PY - 2005/1

Y1 - 2005/1

N2 - A live bovine viral diarrhea (BVDV) vaccine, marketed as a derivate of the Oregon C24V strain, was used between the end of the 1960s and the beginning of the 1990s in Central Europe. Since laboratory investigations of mucosal disease cases in vaccinated animals suggested recombinations between the vaccine and wild type variants of BVDV, and recombinational nucleotide sequences seemed distinct from BVDV Oregon C24V, the aim of the present retrospective study was to analyze the genomes of pre-registration (termed here BVDV-Xpre) and of marketed (BVDV-X) batches of the vaccine. The results of the complete genome analysis of BVDV-Xpre confirmed that the original virus strain used at the start of the vaccine production was Oregon C24V. Surprisingly, the analysis of the complete nucleotide sequence of the BVDV-X marketed vaccine revealed that this strain belongs to the BVDV 1b subgroup, with a 93.7% nucleotide sequence homology to BVDV reference strain Osloss. The homology to BVDV Oregon C24V was significantly lower (77.4%), and a thorough sequence scanning showed that the genome of BVDV-X had not derived from Oregon C24V. These data indicate the very likely scenario that a strain different to Oregon C24V was picked up during the in vitro or in vivo passages for vaccine development. Despite of the virus-switch, the BVDV-X vaccine continuously maintained its innocuity and efficacy, as proven by the regular quality testing data, and the presence of the foreign virus remained unnoticed over many years. The results of this work emphasize that the contamination of commercially available live vaccines with exogenous BVDV strains is a real risk factor, and a unequivocal analysis, including molecular methods, is needed to verify their authenticity.

AB - A live bovine viral diarrhea (BVDV) vaccine, marketed as a derivate of the Oregon C24V strain, was used between the end of the 1960s and the beginning of the 1990s in Central Europe. Since laboratory investigations of mucosal disease cases in vaccinated animals suggested recombinations between the vaccine and wild type variants of BVDV, and recombinational nucleotide sequences seemed distinct from BVDV Oregon C24V, the aim of the present retrospective study was to analyze the genomes of pre-registration (termed here BVDV-Xpre) and of marketed (BVDV-X) batches of the vaccine. The results of the complete genome analysis of BVDV-Xpre confirmed that the original virus strain used at the start of the vaccine production was Oregon C24V. Surprisingly, the analysis of the complete nucleotide sequence of the BVDV-X marketed vaccine revealed that this strain belongs to the BVDV 1b subgroup, with a 93.7% nucleotide sequence homology to BVDV reference strain Osloss. The homology to BVDV Oregon C24V was significantly lower (77.4%), and a thorough sequence scanning showed that the genome of BVDV-X had not derived from Oregon C24V. These data indicate the very likely scenario that a strain different to Oregon C24V was picked up during the in vitro or in vivo passages for vaccine development. Despite of the virus-switch, the BVDV-X vaccine continuously maintained its innocuity and efficacy, as proven by the regular quality testing data, and the presence of the foreign virus remained unnoticed over many years. The results of this work emphasize that the contamination of commercially available live vaccines with exogenous BVDV strains is a real risk factor, and a unequivocal analysis, including molecular methods, is needed to verify their authenticity.

KW - Bovine viral diarrhea virus

KW - Control

KW - Strain switch

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=11944251771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11944251771&partnerID=8YFLogxK

U2 - 10.1051/vetres:2004053

DO - 10.1051/vetres:2004053

M3 - Article

C2 - 15610726

AN - SCOPUS:11944251771

VL - 36

SP - 89

EP - 99

JO - Annales de Recherches Veterinaires

JF - Annales de Recherches Veterinaires

SN - 0928-4249

IS - 1

ER -